Homocysteine is a marker for metabolic syndrome and atherosclerosis. Issue 3 (July 2017)

• Record Type: Journal Article
• Authors: Sreckovic, Branko; Sreckovic, Vesna Dimitrijevic; Soldatovic, Ivan; Colak, Emina; Sumarac-Dumanovic, Mirjana; Janeski, Hristina; Janeski, Nenad; Gacic, Jasna; Mrdovic, Igor
• Is Part Of: Diabetes & metabolic syndrome. Volume 11:Issue 3(2017)
• Page Start: 179
• Page End: 182
• Publication Date: 2017-07
• Subjects: IR insulin resistance -- MS metabolic syndrome -- DM2 diabetes mellitus type 2 -- CVD cardiovascular disease -- CHD coronary heart disease -- CVI cerebrovascular infarction -- HOMA-IR homeostatic model assessment for insulin resistance -- ATP III Adult Treatment Panel III classification -- BMI Body Mass Index -- sBP systolic blood pressure -- dBP diastolic blood pressure -- CRP C-reactive protein -- HDL-C high-density lipoprotein-cholesterol -- LDL-C low-density lipoprotein- cholesterol -- ApoA1 - apolipoprotein A1 -- ApoB apolipoprotein B -- PAI-1 plasminogen activation inhibitor -- Lp(a) lipoprotein (a) -- WC waist circumference -- HC -hip circumference -- WHC -waist-to hip circumference; Atherosclerosis -- Homocysteine -- Insulin resistance -- Metabolic syndrome -- Obesity; Diabetes -- Periodicals; Metabolism -- Disorders -- Periodicals; Diabetes Mellitus -- Periodicals; Metabolic Diseases -- Periodicals; Diabète -- Périodiques; Métabolisme, Troubles du -- Périodiques; Endocrinologie -- Périodiques; Diabète -- Physiopathologie -- Périodiques; Diabetes; Metabolism -- Disorders; Electronic journals; Periodicals; 616.462
• DOI: 10.1016/j.dsx.2016.08.026
• Languages: English
• ISSNs: 1871-4021

Abstract

Abstract: Background: It has been documented that patients with metabolic syndrome (MS) and vascular complications have higher homocysteine levels. Hyperhomocysteinemia correlates with IR, increasing oxidative stress, which causes lesions of vascular endothelium leading to endothelial dysfunction, hypertension and atherosclerosis. Objective: The objectives of the study were to examine homocysteine values, along with cardiovascular risk factors (lipid and apolipoprotein status, CRP, blood pressure), indicators of renal function (microalbuminuria/24 h), glucose regulation and insulin resistance (glucose and insulin level, HbA1c, HOMA-IR, uric acid) and anthropometric parameters (BMI, WC, HC, WHR) in patients with and without MS as a correlation between homocysteine and MS factors. Methods: The study included obese and overweight individuals, aged of 30–75 yrs. classified into two groups: with MS (n = 35) and without MS (n = 41). Results: Patients with MS had increased WC, BMI, BP, glycaemia, HOMA-IR, TG, CRP, microalbuminuria, homocysteine and decreased HDL-C (p < 0.05). Statistically significant difference between groups was found for WC, BMI, sBP and dBP, TG, HDL-C (p < 0.01) and glycaemia, CRP, Apo B, HOMA-IR (p < 0.05). Significant positive correlations were found between homocysteine and sBP (p = 0.036), dBP (p = 0.04), Apo B (p = 0.038) and hyperlipoproteinemia (type IIa, type IIb and type IV) (p = 0.04). Conclusion: Patients with MS had increased abdominal obesity, hypertension, hypertriglyceridemia, inflammation factors, IR, homocysteine and microalbuminuria as markers of endothelial dysfunction. A correlation between homocysteine and hypertension and hyperlipoproteinemia showed that homocysteine could be used as a potential marker for atherosclerosis progression.